There may be a new way to diagnose whether a patient is progressing toward dementia/Alzheimer's or experiencing more benign, age-related memory loss. It amounts to a revamped approach toward analyzing the results of cognitive tests.
The hunt for new biomarkers that can help guide the diagnosis and, eventually, some method of treatment for Alzheimer's has spurred Big Pharma and non-profit groups to fund a careful investigation into the disease's links to Down syndrome.
A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.
The FDA has approved the second imaging agent that can be used to detect a toxic protein found clustered in the fogged brains of Alzheimer's patients, but there's no guarantee it will ever find much of a market.
Researchers at Johns Hopkins say they've been able to track a pair of biomarkers that can shed light on a patient's risk of developing Alzheimer's and pinpoint the disease before telltale symptoms appear.
A newly identified set of microRNAs may give scientists fresh insight into how protein levels in the brains of Alzheimer's patients are regulated.
GE Healthcare has at long last nailed down FDA approval for an imaging agent designed to help evaluate living patients for Alzheimer's disease or dementia. It's the second brain-imaging drug of its kind to gain U.S. regulators' OK, and plans call for rolling it out commercially in 2014.
GE Healthcare has gained FDA approval for an imaging agent designed to help evaluate patients for Alzheimer's disease or dementia. Regulators announced the approval, which designates flutemetamol--now called Vizamyl--as a "radioactive diagnostic drug" for use in PET imaging of the brain in adults being scrutinized for either condition.
Drug developer Amgen has reached out to KineMed with an eye on neurodegenerative biomarkers, paying to use the California biotech's platform to ferret out the causes of brain cell-killing disorders like Alzheimer's disease.
U.K. scientists have charted a new path in attacking Alzheimer's disease, concocting an oral formulation that halted brain tissue death in mice and giving hope for a fresh weapon against biotech's memory-robbing white whale.